OKYO Pharma Limited Publication of a Prospectus (6463X)
May 05 2021 - 5:53AM
UK Regulatory
TIDMOKYO
RNS Number : 6463X
OKYO Pharma Limited
05 May 2021
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLYOR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN,
THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY OTHER
JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OF SUCH JURISDICTION
This announcement is an advertisement and not a prospectus.
Neither this announcement nor anything contained herein shall form
the basis of, or be relied upon in connection with, any offer or
commitment whatsoever in any jurisdiction. Investors should not
purchase any transferable securities referred to in this
announcement except on the basis of information contained in the
prospectus (the "Prospectus") in its final form that is published
by OKYO Pharma Limited in connection with the admission of the
Company's ordinary shares (the "Ordinary Shares") to listing on the
standard segment of the Official List of the Financial Conduct
Authority (the "FCA") and to trading on the main market for listed
securities (the "Main Market") of London Stock Exchange plc (the
"London Stock Exchange"). This announcement is not an offer to
sell, or a solicitation of an offer to acquire, securities in the
United States, Australia, Canada, Japan or in any other
jurisdiction.
For immediate release
5 May 2021
OKYO Pharma Limited
("OKYO" or the "Company")
Prospectus Publication Announcement
OKYO Pharma Limited (LSE: OKYO), a biotechnology company focused
on the discovery and development of novel molecules to treat
inflammatory dry eye diseases and ocular pain , announces the
publication of its Prospectus in relation to the admission of a
further 297,869,806 Ordinary Shares of no par value to listing on
the standard segment of the Official List of the FCA and to trading
on the Main Market of the London Stock Exchange (together, the
"Admission").
Admission
It is expected that Admission will become effective and that
dealings will commence at 8.00 a.m. on 7 May 2021.
The Prospectus will be available from the Company's registered
office at Martello Court, Admiral Park, St Peter Port, Guernsey GY1
3HB and online at
https://www.okyopharma.com/investors/corporate-documents (subject
to applicable securities laws).
An electronic copy of the Prospectus will also be submitted to
the National Storage Mechanism and should be available shortly for
inspection at http:/data.fca.org/#nsm/nationalstoragemechanism.
.
OKYO Pharma Limited is a company incorporated in Guernsey with
company number 65220. The Ordinary Shares are registered with ISIN
GG00BD3FV870, SEDOL code BD3FV87 and TIDM OKYO.
End
Enquiries:
Gary S. Jacob, Chief Executive
Officer
Gabriele Cerrone, Non-Executive +44 (0)20 7495
OKYO Pharma Limited Chairman 2379
Optiva Securities Limited +44 (0)20 3981
(Broker) Robert Emmet 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PDIBGGDUGUGDGBU
(END) Dow Jones Newswires
May 05, 2021 06:53 ET (10:53 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024